Edwards Lifesciences Corporation (EW) — BATS 0/100 — 2026-07-23

Listen to the earnings call audio for free on StockAnalysis

Summary based on Edwards Lifesciences Corporation earnings call on 2026-07-23

BotFlo AI Transformation Score for $EW: 0 (0/100)

Sector AI Transformation Score for $EW: 0 (0/50)

Presentation

(1/5) Q2 overview and long-term structural heart strategy
• 📈 Edwards delivered stronger-than-expected second quarter sales growth of 12.5% with contribution across TAVR, mitral, tricuspid, surgical, and regions.
• 🎯 Management reiterated confidence in roughly 10% average long-term total company sales growth as the company profile spans multiple strategic platforms and regions.
• 🫀 Differentiation is framed as singular focus on transforming structural heart care through early innovation, agile execution, culture, and world-class evidence.

(2/5) TAVR performance, evidence, and raised guidance
• 💰 Global TAVR sales were $1.3 billion, up 10.5%, with similar U.S. and OUS growth, stable ASPs, and modest competitive position gains.
• 🔬 New York Valves data reinforced long-term SAPIEN durability, earlier treatment evidence, and PROGRESS baseline insights into heterogeneous moderate AS.
• 📊 Full-year TAVR sales growth guidance was raised to 8% to 9% from 7% to 9%, with mid- to high single-digit long-term growth expected.

(3/5) TMTT portfolio scale and $2 billion 2030 path
• 📈 TMTT sales reached $195.9 million, up 44.8%, with PASCAL, EVOQUE, and SAPIEN M3 exceeding expectations.
• 🚀 Near-term catalysts include next-gen PASCAL approvals, CLASP IITR and U.S. tricuspid PASCAL launch, EVOQUE center expansion, and measured SAPIEN M3 rollout with MAC indication broadening.
• 🎯 TMTT sales guidance was raised to $760 million to $780 million, supporting a path to $2 billion TMTT revenue in 2030.

(4/5) Surgical RESILIA leadership and ECLIPTIS launch plans
• 📈 Surgical global sales were $284 million, up 5%, driven by RESILIA therapies including INSPIRIS, MITRIS, and KONECT.
• 🔬 COMMENCE 10-year data showed favorable freedom from structural valve deterioration and low SVD-related reoperation even in a relatively young cohort.
• 🏥 U.S. approval of ECLIPTIS surgical left atrial appendage technology supports a major rollout later in 2026 with mid-single-digit Surgical growth still expected.

(5/5) Financial results, raised sales outlook, and capital allocation
• 💵 Total sales were $1.74 billion with adjusted EPS of $0.78; company sales guidance rose to 10% to 11% while EPS guidance of $2.95 to $3.05 was reaffirmed despite tax headwinds.
• 📉 Gross margin was 77.6% with FX pressure; full-year operating margin is expected at the high end of 28% to 29%, about 150 bps constant-currency expansion, then 50 to 100 bps ongoing.
• 🏦 Balance sheet strength included about $2.9 billion cash, priorities of organic growth and manufacturing, structural heart external opportunities, and $1.5 billion remaining repurchase authorization.

Q&A

(1/7) Q&A: TAVR share/market expansion and TMTT upside drivers
• 📈 Bernard said TAVR results were better than expected and durable because of roughly 20 years of technology and evidence that made SAPIEN the global benchmark for performance and durability.
• 🌍 TAVR growth rates were described as very similar between the U.S. and OUS amid renewed clinical-data focus.
• 🧩 TMTT upside was characterized as portfolio-wide, with PASCAL adoption up, EVOQUE accelerating, and early M3 feedback strong in the U.S. and Europe.

(2/7) Q&A: PROGRESS heterogeneity framing and long-term 10% growth
• 🔬 PROGRESS baseline characteristics were split from full results to deepen understanding that moderate AS is at least as large as severe, highly heterogeneous, and similar in age to severe AS.
• ⏳ If positive, PROGRESS is expected to have minimal 2026 impact, with mid- to high single-digit long-term TAVR guidance already accommodating such scenarios and more 2027 detail at the investor conference.
• 🎯 Bernard clarified the 10% comment is long-term total company guidance with TAVR mid- to high single digits, consistent with prior investor-conference and Q1 messaging.

(3/7) Q&A: Q3 seasonality math and TAVR NCD implications
• 📊 Raised full-year 10% to 11% guidance already embeds a strong first half and artificially lower second-half growth rates due to high 2025 comps.
• 📅 Normalized Q3 seasonality means management does not expect last year’s very strong summer; sequential Q2-to-Q3 dollars are still expected to increase somewhat.
• 🏛️ Dan said the draft NCD is encouraging via asymptomatic coverage pathway, coverage without evidence development for symptomatic severe AS, and heart-team modernization, with efficiency more important than a large new-center add.

(4/7) Q&A: PROGRESS adoption path if data are positive
• 🧪 Dan said results must be seen at TCT first and that moderate AS should be thought of like asymptomatic as a new indication without a surgical predicate.
• 📚 Adoption would require change management, behavior change, and education similar to other first-in-class indication expansions.
• ⏳ Important data and learning are expected, but contribution timing was framed as gradual rather than immediately quantified.

(5/7) Q&A: PASCAL tricuspid approval readiness and market positioning
• 📋 Daveen said CLASP IITR data are expected at TCT with current planning for a Q4 U.S. approval, without declaring trial success details beyond that plan.
• 🛠️ European experience suggests PASCAL’s differentiated features such as independent grasping are even more relevant in tricuspid use, supporting physician preference.
• 📈 Bernard framed U.S. PASCAL tricuspid as a fourth TMTT growth layer alongside PASCAL mitral, scaling EVOQUE, and early M3, supporting confidence in the $2 billion 2030 TMTT goal.

(6/7) Q&A: EVOQUE inflection versus broad TMTT strength and PROGRESS drugs
• 🚀 Bernard and Daveen said EVOQUE demand is high and has shown inflection, but TMTT growth is broad-based across PASCAL, EVOQUE, and M3 and across regions.
• 🏥 EVOQUE momentum drivers include weekly/monthly new-center openings plus deeper existing-center utilization through streamlined screening-to-case workflows.
• 💊 Dan clarified PROGRESS is not a heart-failure trial like UNLOAD; patients are moderate AS with at-risk features and healthy LV function, so drug regimens are not a major randomization factor.

(7/7) Q&A: TAVR-in-TAVR lifetime management opportunity
• 🔁 Dan said lifetime management is increasingly critical as earlier treatment means some patients will outlive first-valve durability, creating complex re-treatment planning needs.
• 📊 Edwards has modeled TAVR-in-TAVR into its market model; it is still a relatively small market share today but expected to grow within the overall TAVR market.
• 💪 Bernard positioned TAVR as still underpenetrated with multiple catalysts—NCD/asymptomatic access, potential PROGRESS indication, plus TMTT and Surgical opportunities—supporting durable company growth and margin/EPS leverage confidence.